CompanyKYMRNasdaqWatertown, MA

Kymera Therapeutics, Inc.

Kymera Therapeutics develops targeted protein degradation therapies—oral small molecule degraders for immunological diseases.

SEC EDGAR ClinicalTrials.gov kymeratx.com

SCHEDULE 13G/ASep 8Latest SEC filing

Sep 16Latest story

September 2026

Kymera registers Phase 1 crossover trial testing oral formulations of KT-621

Sep 16Trial updateKT-621 Kymera Therapeutics, Inc.

August 2026

Kymera moves up KT-621 atopic dermatitis data after fast enrollment

Aug 5Quarterly updateKT-621 Kymera Therapeutics, Inc.

June 2026

Kymera registers long-term extension study for KT-621 in asthma patients

Jun 30Trial updateKT-621 Kymera Therapeutics, Inc.